C
루닛
328130KOSDAQ소프트웨어 개발 및 공급업44.3 / 100
Reference Date: 2026-04-13
Financial Score7.5 / 40
News Sentiment13.8 / 25
Momentum9.0 / 20
Disclosure14.0 / 15
AI Analysis: ROE is below the industry average, PBR raises overvaluation concerns. Rose 6.2% over the past month, and news sentiment is positive.
Company InformationBased on 2025 Annual Report
Business Overview
Lunit is a deep learning-based medical AI company specializing in cancer diagnosis and breast cancer screening solutions, leveraging AI-assisted detection and imaging biomarker technologies. Its core products, Lunit INSIGHT and Lunit SCOPE, drive innovation in the medical AI market, with 92% of revenue generated from overseas markets, including the U.S. and Japan.
Number of Employees
272people
Average Salary
93.2M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 14.434.0Point
PBR
7.91Industry Average 1.280.0Point
6.2x industry avg (risky)
ROE
-31.58Industry Average 1.360.0Point
Well below industry avg
Debt Ratio
14.75Industry Average 7.930.5Point
1.9x industry avg (risky)
Trend 2023~20253.0 / 10 points
Revenue Growth Rate
3.0 / 3
Avg ▲84.7% (2-year basis)
Operating Profit Growth Rate
0.0 / 3
Avg ▼41.5% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -32.3% (declining, 3yr)
Detailed News Sentiment
19 totalPositive 2Neutral 12Negative 0Average Sentiment Score 57.1
- Neutral
- Neutral
- Neutral
Detailed Momentum
52-week position3.0Point
52w lower range (26%)
Current 37,100Won52-week high 53,93452-week low 31,087
1-month return4.0Point
1m +6.22% (slight rise)
Volume trend2.0Point
Volume decreasing
Detailed Disclosure
28 totalPositive 2Neutral 26Negative 0
- Neutral주식등의대량보유상황보고서(약식)2026-04-09
- Neutral효력발생안내( 2026.3.24. 제출 증권신고서(지분증권) )2026-04-08
- Neutral[기재정정]증권신고서(지분증권)2026-04-07
- Neutral[기재정정]투자설명서2026-04-07
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-04-03